CIAM
ABUS icon

Caitong International Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Caitong International Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,134
Closed -$15.1K – 2549
2025
Q4 		$15.1K Buy
+3,134
New +$14.1K ﹤0.01% 1054
2025
Q3 		– Sell
-784
Closed -$2.42K – 1879
2025
Q2 		$2.42K Sell
784
-39
-5% -$129 ﹤0.01% 1320
2025
Q1 		$2.87K Buy
+823
New +$2.75K ﹤0.01% 1210

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Caitong International Asset Management's ABUS Position: Q1 2026 in Review

Caitong International Asset Management sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 3,134 shares — an estimated $15.1K sold.

Caitong International Asset Management first reported a position in ABUS in Q1 2025 and held it in 3 quarters. The position peaked at $15.1K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Caitong International Asset Management reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 3,134 Arbutus Biopharma shares in Q1 2026, an estimated $15.1K.
  • Caitong International Asset Management first reported a position in Arbutus Biopharma in Q1 2025 and held it in 3 quarters.
  • Caitong International Asset Management's Arbutus Biopharma position peaked at $15.1K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.